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Abstract
Background: Tributyltin (IV) compounds are promising candidates for drug development. In the current study, we
evaluated in-vitro and in-silico profile of carboxylate derivatives of tributyltin (IV) complexes.
Methods: ADMET and drug-likeliness properties were predicted using MetaPrint2D React, preADMET, SwissADME
and Molsoft tools. SwissTargetPrediction predicted molecular targets for compounds. In-vitro bioactivity was
evaluated by quantifying cytotoxicity against HepG2, THP-1 cell lines, isolated lymphocytes and leishmania
promastigotes as well as measuring protein kinase (PK) inhibition activity.
Results: Results indicate partial compliance of compounds with drug-likeliness rules. Ch-409 complies with WDI
and Lipinski rules. ADMET profile prediction shows strong plasma protein binding except for Ch-409, low to high GI
absorption and BBB penetration (Cbrain/Cblood = 0.942–11; caco-2 cells permeability 20.13–26.75 nm/sec), potential
efflux by P-glycoprotein, metabolism by CYP3A4, medium inhibition of hERG, mutagenicity and capacity to be
detoxified by glutathionation and glucuronidation. Molecular targets include proteases, enzymes, membrane
receptors, transporters and ion channels where Ch-409 targets membrane receptors only. Compounds are
significantly (p < 0.05) cytotoxic against HepG2 cell line and leishmania as compared with normal isolated
lymphocytes. Ch-459 indicates highest toxicity against leishmania (mortality 97.9 ± 3.99%; LC50 0.323 ± 0.002 μg/mL)
whereas Ch-409 possesses maximum cytotoxicity against HepG2 cell line (IC50 0.08 ± 0.001 μg/mL) as well as 97.5
± 1.98% (LC50 0.954 ± 0.158 μg/mL) mortality of leishmania promastigotes. It was observed that antileishmanial
effect was reduced by 16.38%–34.38% and 15–38.2% in the presence of NaN3 and mannitol respectively. PK
inhibition and reactive oxygen species production are possible mechanisms for cytotoxicity.
Conclusions: Selected carboxylate derivatives of tributyltin (IV) complexes possess significant antileishmanial and
cytotoxic potential. These are promising compounds for the development of antileishmanial and anticancer drugs.
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Background
Cancer and leishmaniasis are major threats to humans
causing significant morbidity and mortality worldwide.
Leishmaniasis is caused by transmission of leishmania
parasite through sand fly in both endemic and non-
endemic areas [1]. Lack of effective measures to control
both parasite and sand fly are major factors for the
spread of disease. Current therapies are inadequate to
manage cancer and leishmaniasis due to diversity of mo-
lecular disruptions and development of resistance
respectively. Cancer evolves by deregulating endogenous
functions of molecular proteins, which in turn can be
targeted to impede cancer progression. Anticancer drugs
are developed and investigated against angiogenesis,
extracellular matrix proteins and a variety of signal
transduction pathways, including mitogen-activated
protein kinase (MAPK), Janus-activated kinase, transform-
ing growth factor-beta, p53, Ras, Wnt and Akt signaling [2,
3]. Treatment strategies against leishmaniasis involve killing
parasite by DNA fragmentation, formatting aqueous pores
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in promastigotes cell membrane, oxidative mitochondrial
damage, decreasing mitochondrial membrane potential,
affecting peptidases that constitute leishmania genome and
disrupting kinases responsible for leishmania division and
differentiation [4]. Glycogen synthase kinase that control
leishmania cell cycle, is a new potential target for antileish-
manial drugs [5].
Regression of cancer and leishmaniasis is a challenge
that can be accomplished by developing efficacious and
cost-effective drugs. Among multiple synthetic drugs, or-
ganometallic compounds are prospective candidates for
anticancer and antileishmanial drug discovery [6, 7].
Organometallics including pentavalent antimonials [8]
and platin derivatives [9] have been used for over three
decades for the management of leishmaniasis and cancer
respectively [10]. Sodium stibogluconate and meglumine
antimoniate are first line drugs against all forms of leish-
maniasis [11]. On the other hand, carboplatin, oxalipla-
tin and cisplatin are commonly employed metal based
drugs against ovarian, breast, head/neck, bladder, lung
and colorectal cancers [12]. Efficacy of these compounds
is compromised due to substantial risk of toxicities and
emergence of resistance [8, 12]. Clinical limitations and
inadequate control of subject diseases demand to inves-
tigate new drugs. It is general consensus that there are
other metals in periodic table with therapeutic potential.
Structural diversity and redox and catalytic properties of
organometallics make them promising drug candidates.
Among these, organotin (IV) compounds have caught
the attention of researchers for their prospective biocidal
activities. Carboxylate derivatives of organotin (IV) com-
pounds have been previously investigated for their anti-
cancer and antileishmanial profile [10]. Novel tin based
compounds have been characterized with proven
antibacterial, antifungal and antitumor activities [13, 14].
Considering the growing importance of organotin (IV)
compounds in medicine, the present study was designed
to evaluate the cytotoxic potential of tributyltin (IV)
compounds against cancer cells and leishmania. The
rationale was to appraise metal based drugs that can be
effective and efficacious in managing rapidly spreading
cancers and leishmaniasis. We assessed in-silico drug-
likeliness, ADMET profile and in-vitro anticancer and
antileishmanial activities of new carboxylate derivatives
of tributyltin (IV) ligand.
Methods
Chemicals, cell lines and strains
Standards including surfactin, amphotericin B and vin-
cristine were procured from Sigma-Aldrich (Steinheim,
Germany). Doxorubicin was purchased from Merck
(Darmstadt, Germany). Medium ISP4 for protein kinase
(PK) assay was prepared in the laboratory. Unless stated
otherwise, all other chemicals were purchased from
Sigma-Aldrich (Germany). Human leukemia (THP-1)
(ATCC # TIB-202) and human hepatoma (HepG2)
(RBRC-RCB1648) cell lines were used for cytotoxicity
assays. Streptomyces 85E and Leishmania tropica kwh 23
were used for protein kinase inhibition and antileishma-
nial assays respectively.
Compounds
Carboxylate derivatives of tributyltin (IV) backbone were
selected from library of synthetic compounds present at
our laboratory (Fig. 1). These compounds were selected
based on structural similarity to compounds previously
reported to possess cytotoxic profile [10]. These in-
cluded bis(tributylstannyl) 2,2’-(1,4-phenylenebis(oxy))-




ido)benzoate (Ch-448), tributylstannyl 2-(naphthalene-1-
ylcarbamoyl)benzoate (Ch-450), tributylstannyl (Z)-
4-oxo-4-(phenylamino)but-2-enoate (Ch-458) and tribut
ylstannyl (Z)-4-((2,3-dimethylphenyl)amino)-4-oxobut-
2-enoate (Ch-459). Synthesis and characterization data




PreADMET and Molsoft tools were utilized to determine
the drug-likeliness of tributyltin (IV) compounds and
some marketed drugs [15]. PreADMET calculates drug-
likeliness of compounds based on Lipinski rule, lead-like
rule, CMC-like rule, MDDR-like rules and World Drug
Index (WDI) rule. 2D structural models were drawn in
ChemBioDraw Ultra version 12.0 (Cambridge Software)
and SMILES of each compound were translated into
molfile by online SMILES translator and structure file
generator (National Cancer Institute) [16]. Molfile data
was added into the database to predict drug-likeliness
properties. Drug-likeliness score was calculated from
Molsoft using SMILES as input.
ADMET profile prediction
ADMET profile of tributyltin (IV) compounds was pre-
dicted using PreADMET and SwissADME tools [17].
Molfiles created for each compound were added into
the database and searched for ADMET properties. De-
gree of plasma protein binding (PPB) is categorized in
preADMET as strongly bound if %PPB > 90% and
weakly bound if %PPB < 90%. Blood brain barrier (BBB)
penetration is presented as concentration ratio of
steady-state of radiolabeled compounds in brain (Cbrain)
and peripheral blood (Cblood). Compounds are classified
into high, middle and low absorbing into CNS with
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Cbrain/Cblood values of >2, 2-0.1 and <0.1 respectively.
For assessing intestinal absorption, Caco-2 cell model
categorizes compounds as low, middle and highly per-
meable corresponding to values <4 nm/sec, 4–70 nm/
sec and >70 nm/sec respectively. SwissADME predicts
BBB penetration and GI absorption by BOILED-Egg
method [18]. It also classified compounds as targets of
p-glycoprotein (p-gp) efflux, inhibitors of cytochrome
P450 enzymes CYP2C9, CYP2C19, CYP2D6 and
CYP3A4 and substrates for metabolism by CYP2D6
and CYP3A4. PreADMET anticipated toxicity of com-
pound on models of Ames test with or without meta-
bolic activation by S9 (rat liver homogenate) against
strains of Salmonella typhimurium TA100 and TA1535
and rodent carcinogenicity constructed on National
Toxicology Program and FDA US data on in-vivo 2 year
carcinogenicity tests of mice and rats. Results are
produced are positive or negative mutagenicity or
carcinogenicity.
Metabolism of compounds via phase I and phase II
reactions was predicted using MetaPrint2D React [19,
20] subjected to similarity to known sites of metabolism.
It calculates normalized occurrence ration (NOR) indi-
cating relative likelihood of metabolism, which occurs at
a specific site in the molecule.
Molecular target prediction
Molecular targets were predicted by SwissTargetPre-
diction online tool [21]. Query molecules were drawn
in 2D using the javascript-based molecular editor of
ChemAxon and submitted to the database. SwissTar-
getPrediction envisages molecular targets based on
chemical similarity (2D) and/or structural similarity
(3D) among bioactive molecules. A threshold for 3D
and 2D similarity values has been set to 0.75 and
0.45 respectively. Compounds having values beyond
these thresholds are not listed.
In-vitro screening
Cytotoxicity against THP-1 cell line
Cytotoxicity of tributyltin (IV) compounds against THP-
1 cell line was determined by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) assay [22].
THP-1 cells were cultured in complete growth medium
comprising RPMI-1640 (pH 7.4) supplemented with
2.2 g/L NaHCO3 and 10% v/v heat inactivated fetal
bovine serum (HIFBS). An aliquot of 20 μL of samples
in 1% DMSO in PBS and 180 μL of THP-1 cells were
mixed in 96-well plate. Cells were added at an assay
density of 1 × 104 cells/mL whereas sample/standard was
added to achieve the final concentration of 20 μg/mL.
Fig. 1 Structures of tributyltin (IV) compounds
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The plate was incubated at 37 °C for 72 h in humidified
5% carbon dioxide incubator (Panasonic, Japan MCO-
18 AC-PE). Vincristine and 1% DMSO in PBS were used
as positive and negative controls respectively. After incu-
bation, 20 μL of pre-filter sterilized MTT solution
(4 mg/mL in distilled water) was added in plates and
incubated for 4 h at 37 °C in CO2 incubator. Later,
colored formazan crystals were separated by removing
supernatant and dissolved in 100 μL of DMSO. Reaction
was allowed to stand for 1 h to ensure complete dissol-
ution and absorbance was measured at 540 nm using
microplate reader (Biotech USA, Elx 800).
Cytotoxicity assays against HepG2 cell line
Cytotoxicity was further evaluated against HepG2 cell
line by sulforhodamine B (SRB) colorimetric assay [22].
Dulbecco's Modified Eagle Medium (DMEM) supple-
mented with 10% FBS, 100 μg/mL streptomycin sulfate,
100 IU/mL penicillin G sodium and 0.25 μg/mL ampho-
tericin B was used to culture HepG2 cells in CO2 (5%)
incubator (Panasonic, Japan MCO-18 AC-PE) at 37 °C.
An aliquot of 20 μL (1% DMSO in PBS) of samples was
added to 180 μL of cell culture at an assay density of
1x105 cells/mL in 96-well plate. The plate was incubated
at 37 °C for 72 h in CO2 incubator. Final concentration
of compounds/standard was 20 μg/mL. Doxorubicin and
1% v/v DMSO in PBS ere used as positive and negative
controls respectively. An equivalent number of cells in
twelve wells of 96-well plate were incubated for 1 h at
37 °C and labeled as day zero control. Later, cells were
fixed by adding 50 μL of cold 20% w/v TCA for 1 h at
4 °C. These were washed with tap water, air dried and
stained with 50 μL of 0.057% w/v SRB in 1% v/v acetic
acid for 30 min at room temperature. Cells were again
washed with 1% v/v acetic acid, dried overnight and
200 μL of 10 mM Tris base (pH 10) was used to
solubilize the bound dye for 1 h. Absorbance was mea-
sured at 515 nm using a microplate reader. Percentage
of growth inhibition was calculated as: % inhib-
ition = 100 – [(As – Ao) / (An – Ao) × 100], where, Ao,
As and An are absorbance of day zero control, samples
and negative control respectively. IC50 values were de-
termined using 3-fold dilutions of the samples.
Cytotoxicity against isolated lymphocytes
Lymphocytes were isolated using previously described
protocol with some modifications [23, 24]. Informed
consent was obtained from volunteers and procedure
was conducted according to international ethical guide-
lines after gaining approval from the ethical committee
of the Quaid-i-Azam University. A volume of 3 mL of
blood was obtained from a healthy donor by
venipuncture and diluted (1:1) with PBS. It was layered
over 2 mL Histopaque-1077 and centrifuged at 800 × g
for 20 min. The buffy coat was aspirated into 5 mL of
PBS and centrifuged at 350 rpm for 4 min to pellet the
lymphocytes. The pellet was suspended in 1 mL of
RPMI-1640 and cell density was adjusted to get 1 × 105
cells/mL. For cytotoxicity determination, 20 μL of sam-
ples (20 μg/mL) or vincristine or 1% DMSO in PBS and
180 μL of lymphocyte suspension were incubated in
96-well plate at 37 °C for 24 h in humidified 5% carbon
dioxide incubator (Panasonic, Japan MCO-18 AC-PE).
Phytohaemagglutinin (PHA) was added in medium to
stimulate lymphocyte growth. Afterwards, MTT assay
was done as described above. IC50 values were deter-
mined using 3-fold dilutions of the samples.
Antileishmanial activity
Antileishmanial activity against the promastigotes of
Leishmania tropica kwh 23 was evaluated by a quantita-
tive colorimetric assay using 3-(4,5-dimethylthiazol-2-
yl)-2, 5-diphenyl tetrazolium bromide (MTT) with
minor modifications [25, 26]. Leishmania tropica para-
sites were cultured in Medium 199 supplemented with
10% FBS, 100 μg/mL streptomycin sulfate and 100 IU/
mL penicillin G at 24 °C. A volume of 20 μL of extracts
(100 μg/mL; DMSO ≤ 1% in PBS) and amphotericin B
(0.33–0.004 μg/mL) were incubated with 180 μL of pro-
mastigotes at seeding density 2 × 106 cells/mL in 96-well
flat bottom plate at 25 °C for 72 h. Negative control
wells contained 1% DMSO in PBS. All samples were run
in triplicate. Afterwards, plates were incubated for 4 h at
24 °C with 20 μL of MTT (4 mg/mL in distilled water)
to determine the cell viability. Supernatant from each
well was carefully removed leaving behind formazan
crystals. Colored formazan crystals were dissolved in
100 μL of DMSO by setting those aside for 1 h to ensure
complete dissolution. Cell viability was estimated by
measuring absorbance at 540 nm using microplate
reader and percentage growth inhibition was calculated.
Determining photosensitizing effect against leishmania
Photosensitizing effect of tributyltin (IV) compounds
was determined in three parallel groups [27]. Samples
and controls were exposed for 15 min to sunlight
(168 W/m2 of sun intensity) or sunlight with IR filter or
dark conditions. The relative intensity of sunlight was
measured by a CCD spectrometer (Ocean Optics, model
HR4000). Later, plates were incubated at 25 °C for 72 h
and cell viability was determined by MTT assay as given
above. In this assay, samples were tested at concentra-
tions showing less than 55% inhibition in primary antil-
eishmanial assay to exclude false positive.
Determining ROS mediated antileishmanial activity
Leishmania tropica kwh 23 promastigotes were treated
in three groups [27]. First group was exposed to samples
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along with 0.1 mM sodium azide (NaN3), second group
to samples with 1 mM mannitol and third group
comprised of all controls. In third group, promastigotes
were treated in different wells with samples only (sample
control), 1% DMSO in PBS only (negative control-I),
amphotericin B only (positive control), 0.1 mM NaN3
only (negative control-II) and 1 mM mannitol only
(negative control-III). Plates were incubated followed by
MTT assay described above.
Protein kinase inhibition assay
Protein kinase inhibitory activity of the tributyltin (IV)
compounds was measured against Streptomyces 85E
strain using previously described protocol [28]. Culture
of Streptomyces 85E was refreshed in tryptic soy broth
and 100 μL of this was swabbed on sterile ISP4 medium
under aseptic conditions. Sterile filter paper discs
(6 mm) impregnated with 5 μL of samples (10 mg/mL in
DMSO) or surfactin (2 mg/mL in DMSO; positive
control) or DMSO (negative control) were placed on
Streptomyces swabbed petri plate and incubated for
72-96 h at 30 °C. Diameter (mm) of zone of inhibition
(ZOI) around all samples and controls was measured as
clear zone (CZ) and bald zone (BZ). Clear zone repre-
sents Streptomyces growth inhibition whereas bald zone
shows inhibition of hyphae and spore formation. BZ is
indicative of PK inhibition.
Statistical analysis
Data is presented as Mean ± SD of respective parameters
in triplicate analysis. One Way Analysis of Variance
(ANOVA) was applied to measure significance of results.
p < 0.05 was considered statistically significant. Analysis
was done using GraphPad Prism 5.0 software.
Results and discussion
Drug-likeliness prediction
Drug-likeliness prediction is important to optimize
pharmaceutical and pharmacokinetic properties of com-
pounds [29]. Tributyltin (IV) carboxylate compounds
partially comply with selected rules of drug-likeliness.
Ch-409 was in 90% cutoff range of WDI rule and com-
plies with all conditions of Lipinski rule. Ch-458, 431,
448, 459 and 442 are mid-structures whereas Ch-450 is
drug-like according to MDDR-like rule (Fig. 2). In prac-
tice, we have drugs in market that do not completely
comply with drug-likeliness rules but are used due to
their high beneficial effects for humans to treat cancer.
For example, vincristine, which violates CMC-like, lead-
like and Lipinski rules and complies with MDDR-like
rule. Besides, cisplatin does not completely comply with
any of the above rules. Drug-likeliness scores computed
from Molsoft tool also indicate these compounds as
moderately drug-like. Higher the score, greater the drug-
likeliness conforming to available drugs [30]. Tributyltin
(IV) compounds scores are -1.11, 0.42,–0.23, 0.15, 0.40,–
0.49 and 0.27 for Ch-409, Ch-431, Ch-442, Ch-448,
Ch-450, Ch-458 and Ch-459 respectively. On the other
hand, cisplatin, vincristine, doxorubicin, amphotericin B,
dactinomycin and sorafenib have drug-likeliness scores
of -1.12, 1.38, 1.02, 0.9,–1.00 and 0.51 respectively. Thus,
our compounds have comparable drug-likeliness profile
with marketed drugs and are good drug candidates.
ADMET prediction
ADME analysis done by PreADMET predicts that tribu-
tyltin (IV) carboxylate compounds have middle to high
BBB permeability based on Cbrain/Cblood ratio of 0.942–
11 whereas SwissADME predicts no BBB crossing since
these compounds are also substrates for p-glycoprotein
efflux (Table 1). P-gp is present on the apical surface of
endothelial cells of blood brain barrier and impedes the
entry of various drugs [31]. All compounds strongly bind
with plasma protein except Ch-409 and have low to high
GI absorption (caco-2 cells permeability 20.13–
26.75 nm/sec). These compounds can be formulated into
oral dosage form. Ch-409 is inhibitor of CYP2C19;
Ch-450 and Ch-409 are inhibitors of CYP2C9; Ch-458,
Ch-431, Ch-450, Ch-448, Ch-459 and Ch-442 are of
CYP2D6 and Ch-450, Ch-409 and Ch-448 inhibit
Fig. 2 Drug-likeliness profile of tributyltin (IV) compounds: The color from black to white indicates decrease in compliance with drug-likeliness
rules. Placement of arrows on compliance bar shows the extent to which a compound conform to respective rule depending upon number of
the conditions fulfilled for each rule. It is predicted from PreADMET
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CYP3A4. No compound is substrate of CYP2D6 whereas
all others except Ch-409, Ch-458 and Ch-442 are strong
substrates for metabolism by CYP3A4. Our compounds
were found mutagenic in Ames test either by point or
frame-shift mutations (Table 1). Metabolic activation
predicts mutagenicity of metabolites of Ch-458, Ch-450
and Ch-442. Carcinogenicity prediction was “out of
range” in the database expect for Ch-409, which was not
carcinogenic in rat model. Human ether a go-go-related
(hERG) gene encodes cardiac potassium channels that
mediate repolarization phase. Inhibition of these prolong
QTc interval along with the risk of cardiac arrhythmias
[32]. Our compounds show medium risk of hERG inhib-
ition. Since, compounds show very high PPB and very
low IC/LC50 values in in-vitro analysis; therefore, it is
necessary to assess the concentration at which hERG
inhibition risk is predominant.
Metabolic sites predicted by MetaPrint2D React are
highlighted as red (0.66 ≤NOR ≤ 1.00), orange (0.33 ≤
NOR < 0.66), green (0.15 ≤NOR < 0.33), white (0.00 ≤
NOR < 0.15) and grey (little/no data) corresponding to
NOR where high NOR means most frequently reported
site in metabolism database (Fig. 3). It was found that
besides dealkylation, hydroxylation and oxidation, all
compounds are possibly metabolized by multiple phase I
and phase II reactions. Ch-409 can undergo acetylcysteina-
tion and glutathionation; Ch-431 is metabolized by demeth-
ylation and glucuronidation; Ch-448 by glucuronidation;
Ch-450 go through epoxidation, glutathionation, sulfon-
ation, oxidative deamination and methoxylation whereas
Fig. 3 Predicted metabolic sites and metabolites of tributyltin (IV) compounds. Structures with colored circles indicate the metabolic sites predicted by
MetaPrint2D React. Color codes are given based on normalized occurrence ratio. Red = 0.66≤NOR≤ 1.00; orange = 0.33≤NOR< 0.66; green = 0.15≤
NOR < 0.33; white = 0.00≤NOR < 0.15 and grey = little/no data. Two possible metabolites for each compound are given with NOR≥ 0.33
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epoxidation, glucuronidation, methiolation, methoxylation
are predicted for Ch-458 and epoxidation, glutathionation
and methoxylation for Ch-459 (Fig. 3). Glucuronidation
and glutathione metabolism of compounds make these
hydrophilic and ionized at physiological pH. This also
reduces their affinity with cellular target [33]. It is proposed
that metabolism at multiple sites will excrete the com-
pounds out of the body with less side effects of metabolites.
Molecular target prediction
Molecular target prediction by SwissTargetPrediction tool
provided possible interaction sites for tributyltin (IV)
compounds. These include proteases, enzymes, transcrip-
tion factor, receptors, ion channels and other proteins
(Fig. 4). Although the probabilities of interaction with tar-
gets was low (range: 0.01–0.1) based on ChEMBL data-
base; however, in-vitro analysis depicts good bioactivity
profile of these compounds. This means that they interact
strongly with cellular proteins and modify their functions
to kill cancer cells and leishmania parasite. It was pre-
dicted that Ch-409 can bind with membrane receptors
such as opioid (mu, kappa, delta) and nociceptin recep-
tors. On the contrary, Ch-431 dominantly aims enzymes
(47%) acetylcholinesterase, inosine-5'-monophosphate de-
hydrogenase 2 and tyrosyl-DNA phosphodiesterase 1;
transcription factor (7%) hypoxia-inducible factor 1-alpha
and other proteins (33%) including microtubule-
associated protein tau and muscleblind-like protein 1, 2
and 3. Ch-442 was predicted to interact with serine prote-
ases (60%) cathepsin G, granzyme B and H,
chymotrypsin-C and chymotrypsin-like elastase family
member 2A and enzymes (40%) peptidyl-prolyl cis-trans
isomerase FKBP1A and B and peptidyl-prolyl cis-trans
isomerase FKBP4 and 5. Ch-448 can regulate transporters
(47%), for examples, excitatory amino acid transporters 1,
2, 3, 4 and 5. Other proteins include tyrosyl-DNA
phosphodiesterase 1, FAD-linked sulfhydryl oxidase ALR;
muscleblind-like proteins and membrane metallo-
endopeptidase-like 1 (soluble form). Ch-450 targets 67%
proteases (alpha-trypsin chain 1, trypsin 2 and 3, activa-
tion peptide fragment 1, urokinase-type plasminogen acti-
vator long chain A, tissue-type plasminogen activator,
hepatocyte growth factor activator long chain,
apolipoprotein-a), 7% other enzymes (enzyme FAD-linked
sulfhydryl oxidase ALR), 13% transcription factors (oxy-
sterols receptor LXR-alpha and beta) and 13% unclassified
proteins (plectin, microtubule-associated protein tau).
Ch-458 can dominantly control serine proteases (73%)
including chymase, chymotrypsin-C, cathepsin G, Gran-
zyme B and H, chymotrypsin-like elastase family member
1, 2A, 2B, 3A and 3B and neutrophil elastase as well as
acetylcholinesterase, poly [ADP-ribose] polymerase 14
and microtubule-associated protein tau. Besides enzymes
(74%; telomerase reverse transcriptase, cathepsin G,
monoglyceride lipase), Ch-459 can also interact with ion
channels (13%) like ATP-sensitive inward rectifier potas-
sium channels 11, 1 and 8. It has been previously reported
that some of these proteins are positive and negative regu-
lators of cancer. For examples, microtubule-associated
protein tau is associated with paclitaxel resistance in
breast and gastric cancer patients [34, 35] and upregulated
hepatocyte growth factor activator and trypsin like prote-
ases in cancer tissues are involved with carcinogenesis and
metastasis [36]. In contrast, muscleblind-like protein 1 is
implicated in suppression of breast cancer metastatic
colonization [37]; granzymes play key role in antitumor
immunity [38] and FKBP1A is a target for anticancer drug
rapamycin [39]. Predicted interaction of our compounds
with previously reported proteins in cancer provides
evidence for their beneficial role.
Cytotoxicity of tributyltin (IV) compounds
Cytotoxicity of tributyltin (IV) compounds was quanti-
fied against HepG2, THP-1 cell lines and isolated
Fig. 4 Predicted molecular targets for tributyltin (IV) compounds. Molecular target prediction is done by SwissTargetPrediction tool. Each bar
represents the targets for each compound based on structural homology and binding potential of similar compounds in database. Unclassified
shows the proteins that are not classified into any group
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lymphocytes at 20 μg/mL to compare effect at same
concentration (Table 2). All compounds showed signifi-
cantly higher (p < 0.05) cytotoxicity against HepG2 cell
line except Ch-442. Ch-450 and Ch-459 exhibited sig-
nificant cytotoxicity against THP-1 cells whereas activity
of other compounds was lower than 50% at same con-
centration. On the contrary, Ch-409, Ch-459 and
Ch-442 were toxic against normal isolated lymphocytes.
However, IC50 values of these compounds for HepG2
cells were 10–100 times lower than those for isolated
lymphocytes (Table 2). There was no significant cytotox-
icity of other compounds against normal cells. This
partially selective response against cancer cell lines is
beneficial in targeting cancer cells whereas limiting dam-
age to normal cells. Results are comparable with stand-
ard doxorubicin against HepG2 cells while lower in case
of vincristine against THP-1 cells and lymphocytes. It
can be seen that vincristine is significantly toxic against
normal lymphocytes. Our compounds showed cytotox-
icity against HepG2 cell line comparable to previously
reported data on oxaliplatin and cisplatin [40]. On the
contrary, lymphocyte cytotoxicity was more pronounced
in carboplatin and cisplatin [23].
It was reported that carboxylate derivatives of organo-
tin such as phenylacetate, benzoate and cinnamates were
found effective against tumor cell lines. Some of the di-
n-butyltin compounds were proved more potent than
cisplatin [41]. In line with this, our results are compar-
able with previous study where different organotin (IV)
carboxylate compounds revealed significant anticancer
activity against kidney fibroblast (BHK-21) and lung car-
cinoma (H-157) cell lines [10]. This indicates prospective
of tributyltin (IV) carboxylate compounds as potential
candidates for anticancer drug development. Further
screening of compounds used in present study is recom-
mended against a range of cancer and normal cell lines
to evaluate their efficacy and selectivity. Several reports
presented that there is no well-defined mechanism by
which organotin compounds can interact with cancer
cells. Their intercalation with phosphodiester backbone
of DNA is reported, altering intracellular breakdown of
phospholipids of endoplasmic reticulum [42, 43]. Orga-
notin compounds may also bind with membrane
proteins, cellular kinases, ATPase or glycoproteins [44].
We have found these compounds as protein kinase
inhibitors, which can be one of the mechanisms for
cytotoxicity. However, detailed mechanism of action of
these compounds is to be elucidated.
Antileishmanial activity
Tributyltin (IV) compounds demonstrated highly signifi-
cant (p < 0.05) antileishmanial activity with >90% lethality
and very low LC50s ranging from 0.954 ± 0.158 μg/mL to
0.078 ± 0.002 μg/mL (Table 3). Lowest LC50 was observed
by Ch-431 that appears equipotent to the standard
amphotericin B. It has been reported that sodium stibo-
gluconate showed IC50s of 64 μg/mL and 22 μg/mL
against axenic log-phase promastigotes and cellular meta-
cyclic promastigotes respectively [45]. Our compounds
appear to be more potent than sodium stibogluconate.
Compounds were further tested for their photocatalytic
activity by exposing to sunlight, sunlight with IR filter and
dark conditions. There was 0–32% toxicity against leish-
mania when exposed to light and dark conditions without
samples. Compounds showed no significant photosensitiz-
ing effect after normalizing the data indicating that their
activity is independent of light conditions. Samples were
further tested in the presence of ROS scavengers NaN3
and mannitol, which scavenge singlet oxygen [46] and
hydroxyl radicals [47] respectively. ROS are important
molecules in controlling leishmania infection that are
generated by macrophages during phagocytosis of parasite
[48]. It was observed that antileishmanial activity of com-
pounds was reduced by 16.38%–34.38% in the presence of
NaN3 whereas it was reduced by 15–38.2% in the presence
of mannitol as compared with 16% and 10% decline for
amphotericin B in the presence of NaN3 and mannitol
respectively. Ch-442 showed selective toxicity against
leishmania with 95.8 ± 1.16% lethality as compared
with 12.8 ± 0.37% and 44.6 ± 0.18% cytotoxicity against
HepG2 and THP-1 cells respectively. Moreover, antil-
eishmanial L50 (0.088 ± 0.009 μg/mL) is approximately
15 times lower than IC50 (14.9 ± 0.25 μg/mL) against
isolated lymphocytes. Activity of Ch-442 was reduced
by 22% and 38.2% in the presence of NaN3 and man-
nitol respectively. These results indicate that ROS
production by compounds is one of the mechanisms
for antileishmanial effect.
Structure-activity relationship
Tributylstannyl carboxylate is the primary moiety re-
sponsible for cytotoxicity of these compounds. We com-
pared all compounds with Ch-458, which has double
bond at position 2, phenylamino ring and one tributyl-
stannyl group with an IC50 of 1.58 μg/mL against
HepG2 cells. Replacing the oxo-phenylaminobutanoic
acid ligand with phenylenebis(oxy) diacetic acid has en-
hanced the potency of Ch-409 by 19-fold providing max-
imum cytotoxicity with lowest IC50 value. Dimethyl
substitution at phenylamino ring in Ch-459 augmented
its potency by 2.54-fold compared to Ch-458. On the
contrary, substitutions of naphthalene-1-ylcarbamoyl,
ethoxycarbonyl at position 4 on phenylamino group and
missing double bond at position 2 reduced potency of
compounds Ch-450, Ch-431 and Ch-448 by 1.77, 3.46
and 2.18-folds respectively. However, presence of cyclo-
hexyl ring instead of phenyl may have hindered binding
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affinity of Ch-442 to target proteins in HepG2 cells caus-
ing no cytotoxicity.
In case of THP-1 cells, addition of naphthalene
(Ch-450) and dimethylphenyl (Ch-459) might have en-
hanced binding of compounds to specific targets in THP-
1 cells that vary from HepG2 and isolated lymphocytes.
Nevertheless, the cytotoxicity is only around 50% at con-
centration of 20 μg/mL. Since, proteins and cellular com-
ponents may vary between normal and cancer cells;
therefore, activity of our compounds was pronounced
against HepG2 cells with little/no effect against isolated
lymphocytes. Substitutions of cyclohexyl ring (Ch-442),
dimethylphenyl (Ch-459) and phenylenebis(oxy) diacetic
acid (Ch-409) showed cytotoxicity against isolated lym-
phocytes. It is possible that these compounds gained ac-
cess to biomarkers similar in normal and cancer cells.
Since, Ch-459 showed cytotoxicity in all three cell types
used; therefore, presence of dimethylphenyl group appears
to be an important modulator of cytotoxicity.
Compounds were also highly cytotoxic against leish-
mania promastigotes. Ch-409 with phenylenebis(oxy)
diacetic acid ligand was least potent among all com-
pounds with LC50 0.954 μg/mL. Substitution of ethoxy-
carbonyl at position 4 on phenylamino group (Ch-431)
gained maximum access to specific leishmania proteins
and was 12.23-fold potent than Ch-409. Cyclohexyl moi-
ety in Ch-442 showed targeted affinity for leishmania
specific proteins or other biomolecules allowing selective
cytotoxicity behavior with 10.84-fold higher potency
than Ch-409 and 1.12-fold lower than Ch-431. Similarly,
respective substitutions in Ch-458, Ch-459, Ch-450 and
Ch-448 reduced potency by 3.28, 4.14, 4.62 and 7.38-
folds compared with Ch-431. Reduction of a double
bond at position 2 drastically decreased potency of Ch-
448. Thus, tributylstannyl carboxylate backbone is highly
cytotoxic against leishmania promastigotes and ligand
modifications on it caused potency variations. Our results
indicate dissimilarity in compounds’ behavior against can-
cer cells, normal cells and leishmania. It depicts that these
have different molecular targets as well as variable affinity
against same biomolecules. This is supported by our in-
silico molecular target prediction where both variable and
overlapping interaction site have been predicted. Thus,
these compounds have multimode cytotoxicity with po-
tential for varied diseases.
Protein kinase inhibition activity
Protein kinases are essential modulators of cellular regu-
lations and physiological processes [49]. Irregular activa-
tion of these kinases constitutes oncogenic signals.
Cytoplasmic (Abl) or transmembrane (PDGFR, EGFR)
protein kinases found in many cancer cells are targets
for anticancer drugs to induce cytotoxicity [50]. Thus,
we assessed inhibition of protein kinases as possible
mechanism of cytotoxicity in our study.
Being highly cytotoxic, initially clear zones were
observed; however, compounds provided bald zones at
lower doses with no cytotoxicity. Bald zone specify pro-
tein kinase inhibition by obstructing aerial hyphae for-
mation whereas clear zones indicate complete inhibition
of Streptomyces growth. Lowest MIC for PK inhibition
was shown by Ch-431 (Table 2). MIC for PK inhibition
is much lower than IC50 for HepG2 cytotoxicity and is
somewhat comparable with LC50 for antileishmanial
activity. It means that these compounds are effective in
targeting protein kinase enzymes and other associated
factors at lower doses that those which cause
cytotoxicity.
Molecular target prediction predicted enzymes as
likely targets. Although, in-silico target prediction shows
little data on binding probability with kinases; however,
we experimentally proved this fact that tributyltin (IV)
carboxylate compounds used in our study significantly
inhibited (p < 0.001) protein kinase activity in Streptomy-
ces. Streptomyces requires protein kinase activity of
RamC to convert pre-Sap B to Sap B, a surfactant im-
portant for aerial hyphae formation [51]. It has been
found that RamC is a membrane associated receptor
kinase [51], which supports binding of all our com-
pounds with this motif including Ch-409 whose major
targets are predicted to be receptors only. This indicates
significance of tributyltin (IV) compounds in protein
kinase inhibition that may be a reason for cytotoxicity in
cancer cells and leishmania. Oncogenesis is mediated
either directly or indirectly by transmembrane or
cytoplasmic tyrosine/serine-threonine kinases [52]. Fur-
thermore, MAPK MAPK-like kinases, cyclin-dependent
kinase (Cdk) and glycogen synthase kinase 3 are impli-
cated in growth, differentiation and infectivity of leish-
mania parasite [53]. Thus, our data suggests molecular
level studies to further explore exact mechanism of these
compounds.
Conclusions
Tributyltin (IV) carboxylate compounds are contenders
of anticancer and antileishmanial drug development. In-
silico analysis shows these compounds partially drug-
like, permeable across GI membrane and blood brain
barrier and mutagenic with possible risk of hERG inhib-
ition. High PPB and rate of metabolism will provide very
low free drug concentration in plasma that may reduce
the risk of side effects, which can be further managed
using targeted drug delivery system. Our new com-
pounds are highly cytotoxic against HepG2 cells and
leishmania parasite with lower cytotoxicity against nor-
mal isolated lymphocytes. These significantly inhibit
Waseem et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:8 Page 12 of 14
protein kinase with very low IC50 values. These com-
pounds can be evaluated further based on their risk
benefit ratio.
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